Cagent Vascular today announced the first-in-human cases with its Serranator Sonic IVL system alongside significant funding. In addition to the first human use of the intravascular lithotripsy (IVL) system, the company closed a $41 million Series D round. Serranator Sonic IVL's first human procedures took place in Uzbekistan as part of its … [Read more...] about Cagent Vascular reports first-in-human IVL cases, closes $41M Series D
cagentvascular
Cagent Vascular initiates balloon angioplasty study
Cagent Vascular announced that it enrolled the first patient in a study comparing its Serranator system to plain old balloon angioplasty (POBA). The prospective, randomized (2:1 treatment to control) dual-center study plans to enroll up to 60 subjects. Investigators intend to use optical coherence tomography (OCT) imaging to demonstrate the … [Read more...] about Cagent Vascular initiates balloon angioplasty study
Cagent Vascular wins FDA clearance for balloon catheter
Cagent Vascular announced that it received FDA 510(k) clearance for its Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter. The FDA indication is for use of the Serranator for treating below-the-knee (BTK) lesions, making it the first and only angioplasty balloon with FDA clearance and CE Mark approval that embeds … [Read more...] about Cagent Vascular wins FDA clearance for balloon catheter
